Advertisement
EMITF vs NUWE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EMITF is a Hold and NUWE is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NUWE’s FA Score shows that 1 FA rating(s) are green while.
- NUWE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EMITF’s TA Score shows that 5 TA indicator(s) are bullish while NUWE’s TA Score has 4 bullish TA indicator(s).
- EMITF’s TA Score: 5 bullish, 3 bearish.
- NUWE’s TA Score: 4 bullish, 3 bearish.
Price Growth
NUWE (@Medical Specialties) experienced а -13.29% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +3.10%. For the same industry, the average monthly price growth was +5.13%, and the average quarterly price growth was -1.85%.
Industries' Descriptions
@Medical Specialties (+3.10% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| EMITF | NUWE | EMITF / NUWE | |
| Capitalization | 11.9M | 2.42M | 492% |
| EBITDA | -294K | -16.36M | 2% |
| Gain YTD | 23.333 | -70.335 | -33% |
| P/E Ratio | N/A | 0.02 | - |
| Revenue | 0 | 8.86M | - |
| Total Cash | N/A | 3.8M | - |
| Total Debt | N/A | 760K | - |
EMITF | NUWE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 95 | 88 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 21 Undervalued | 28 Undervalued | |
PROFIT vs RISK RATING 1..100 | 61 | 100 | |
SMR RATING 1..100 | 89 | 100 | |
PRICE GROWTH RATING 1..100 | 50 | 65 | |
P/E GROWTH RATING 1..100 | 100 | 97 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EMITF's Valuation (21) in the Real Estate Development industry is in the same range as NUWE (28) in the Medical Specialties industry. This means that EMITF’s stock grew similarly to NUWE’s over the last 12 months.
EMITF's Profit vs Risk Rating (61) in the Real Estate Development industry is somewhat better than the same rating for NUWE (100) in the Medical Specialties industry. This means that EMITF’s stock grew somewhat faster than NUWE’s over the last 12 months.
EMITF's SMR Rating (89) in the Real Estate Development industry is in the same range as NUWE (100) in the Medical Specialties industry. This means that EMITF’s stock grew similarly to NUWE’s over the last 12 months.
EMITF's Price Growth Rating (50) in the Real Estate Development industry is in the same range as NUWE (65) in the Medical Specialties industry. This means that EMITF’s stock grew similarly to NUWE’s over the last 12 months.
NUWE's P/E Growth Rating (97) in the Medical Specialties industry is in the same range as EMITF (100) in the Real Estate Development industry. This means that NUWE’s stock grew similarly to EMITF’s over the last 12 months.
| EMITF | NUWE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 63% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 54% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 57% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 54% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 53% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 42% | 2 days ago 79% |
| Advances ODDS (%) | N/A | N/A |
| Declines ODDS (%) | N/A | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 49% | 2 days ago 90% |
Advertisement
EMITF and
Correlation & Price change
A.I.dvisor indicates that over the last year, EMITF has been loosely correlated with STSS. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if EMITF jumps, then STSS could also see price increases.
| Ticker / NAME | Correlation To EMITF | 1D Price Change % | ||
|---|---|---|---|---|
| EMITF | 100% | N/A | ||
| STSS - EMITF | 38% Loosely correlated | +3.45% | ||
| AVHHL - EMITF | 26% Poorly correlated | N/A | ||
| GCTK - EMITF | 22% Poorly correlated | +15.14% | ||
| NUWE - EMITF | 22% Poorly correlated | -3.49% | ||
| EMBC - EMITF | 21% Poorly correlated | +8.79% | ||
More | ||||
NUWE and
Correlation & Price change
A.I.dvisor tells us that NUWE and PRE have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NUWE and PRE's prices will move in lockstep.
| Ticker / NAME | Correlation To NUWE | 1D Price Change % | ||
|---|---|---|---|---|
| NUWE | 100% | -3.49% | ||
| PRE - NUWE | 24% Poorly correlated | +6.28% | ||
| TMDX - NUWE | 23% Poorly correlated | +4.14% | ||
| HBIO - NUWE | 23% Poorly correlated | +25.46% | ||
| CRL - NUWE | 22% Poorly correlated | +2.81% | ||
| EMITF - NUWE | 22% Poorly correlated | N/A | ||
More | ||||